Bioimaging Study of 89Zr-M7824 in NSCLC
A Bioimaging Study of 89Zr-M7824 PET Scans in Patients With Advanced or Metastatic NSCLC Receiving M7824 Alone or in Combination With Chemotherapy
Sponsor: Austin Health
Terminated
Efficacy finding
Other terminated trials from Austin Health
Other Non-Small Cell Lung Cancer trials with similar outcome
Listed as NCT04297748, this PHASE1/PHASE2 trial focuses on Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Austin Health, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Sep 2021 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Austin Health
- Merck Healthcare KGaA
- Olivia Newton-John Cancer Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .